RNS REACH | 24 April 2024

ImmuPharma PLC

("ImmuPharma" or the "Company") 

IMMUPHARMA AT BIO-EQUITY 2024

12-14 May 2024, SAN SEBASTIAN

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Equity. The event will be held from 12-14 May 2024, in San Sebastian, Spain.

BIO-Equity is an annual premier partnering event, designed to provide biotechnology companies with the opportunity to present to and connect with investors together with the global biopharma community. This event provides an important continuum for ImmuPharma to facilitate ongoing discussions regarding potential global partnering deals across its pipeline portfolio. 

Commenting on the event, Tim McCarthy, CEO of ImmuPharma said: "Further to our clinical progress with P140 in SLE and CIDP, attending BIO-Equity 2024 offers the opportunity to continue discussions on our unique portfolio with specific bioPharma companies and investment specialists, particularly in relation to SLE, CIDP and potentially other autoimmune diseases within our P140 technology platform. Our focus remains on track to establish global partnering opportunities across all our programs."

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Lupus (Systemic Lupus Erythematosus / SLE)

Lupus is a chronic inflammatory disease which is thought to affect some 16 million individuals worldwide. The current standard of care still consists of steroid and anti-malarial therapies which many have side-effects and poor response in many patients. Recently more targeted monoclonal therapies are GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There still exists a high unmet medical need for a drug that has a strong efficacy and safety profile.

About CIDP (Chronic Idiopathic Demyelinating Polyneuropathy)

CIDP is a rare acquired autoimmune disorder of peripheral nerves which is thought to affect some 90 thousand individuals across US/Europe.  It is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. CIDP related disability may be substantial. In addition to the physical burdens imposed by the disease, those affected by CIDP also frequently experience economic and emotional hardship and are often burdened not only by the disease but also by the immunotherapies used to treat the disease. Other than intravenous (IVIG) and subcutaneous immunoglobulin (SCIG), corticosteroids and plasma exchange are the only other treatment options. There is still a huge unmet need for more efficacious drugs that are safer, and which affect underlying disease progression.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.